Background: On-treatment predictors during antiviral therapy of HCV are useful because they allow discontinuation of an unnecessary treatment in non-responders. Our aim was to evaluate the usefulness of plasma and erythrocyte ribavirin levels in predicting sustained virological response (SVR) in HCV genotype 1 patients undergoing antiviral treatment. Methods: A total of 40 HCV genotype 1 patients treated with pegylated interferon-α2a 180 µg weekly plus ribavirin 1,000 or 1,200 mg daily (according to body weight) were included in the study. Plasma and erythrocyte ribavirin levels were evaluated in all patients at week 12 by HPLC. At week 24, ribavirin levels were reassessed in those achieving early virological response (EVR). Results: A total of 27 patients achieved EVR, whereas 17 achieved SVR. There was no difference among EVR and non-EVR patients in terms of plasma and erythrocyte ribavirin concentrations at week 12. At week 24, EVR patients obtaining SVR exhibited higher mean ±sd levels of ribavirin in plasma and lower levels in erythrocytes compared with non-SVR patients (in plasma 12.8 ±10 versus 5.8 ±4 µM [P<0.02] and in erythrocytes 1,053 ±504 versus 1,613 ±589 µM [P<0.03]). When the plasma ribavirin/erythrocyte ribavirin ×100 ratio was compared, the difference was enhanced (1.5 ±1.3 versus 0.4 ±0.3 µM; P<0.01). Receiver operating characteristic curve analysis identified a cutoff for plasma ribavirin/erythrocyte ribavirin ×100 ratio in predicting SVR of 0.71 with a negative predictive value of 0.8 and a positive predictive value of 0.9, whereas those related to EVR were 1 and 0.6, respectively. Conclusions: Plasma ribavirin/erythrocyte ribavirin ×100 ratio at week 24 seems to be a good indicator of SVR in HCV genotype 1 patients achieving EVR.
genotype-1-infected patients have been confirmed by several studies to experience a lower SVR rate in comparison to those infected by genotypes 2 or 3 (approximately or equal to 45% versus 80%, respectively) [4] [5] [6] . For this reason, HCV genotype 1 is generally regarded as difficult to treat. Response during therapy is mainly on the basis of the trend of HCV RNA serum decay assessed by an approved quantitative reverse transcriptase (RT)-PCR method. Patients not achieving early virological response (EVR), defined as a viral load decrease ≥2 log (or undetectable HCV RNA) at week 12 of treatment, become non-responders to therapy in 97-100% of cases [7] [8] [9] . 
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By contrast, EVR is not accurate in predicting SVR, particularly in patients infected with HCV genotype 1 because only 60% of these patients will experience viral clearance after EVR. Another virological on-treatment predictor, rapid virological response (RVR), defined as negative HCV RNA at week 4 of treatment, is nearly 90% accurate in predicting SVR. However, no more than 2 out of 10 HCV genotype-1 -infected patients are able to achieve RVR during the course of antiviral treatment [9] [10] [11] . Other virological parameters, such as HCV quasispecies, have been investigated during treatment as possible predictors, but they were not better on-treatment indicators than HCV RNA decay [12] . Novel indicators that predict a successful therapeutic outcome during treatment could be derived from treatment dosage and duration. Interestingly, the amount and time of exposure to ribavirin has been consistently reported to affect overall therapeutic results [13] [14] [15] ; however, it is important to note that a high variability in ribavirin bioavailability has been described in different patients [16, 17] . This is also confirmed by the observation that on-treatment adverse events (such as anaemia) are less associated with the dose administered per kg of body weight than to the specific plasma or erythrocyte ribavirin concentration achieved by an individual at a particular time point during the therapeutic course [18, 19] . In this prospective study, we reassessed this issue by evaluating plasma and erythrocyte ribavirin levels during the course of therapy in patients with HCV genotype 1 chronic hepatitis as possible on-treatment indicators of a successful outcome. Our results show that these parameters might be helpful in identifying patients who achieve SVR. In particular, a specific ratio among plasma and erythrocyte ribavirin concentrations (at week 24) was identified as a predictor of SVR in EVR patients with a greater accuracy compared with common on-treatment viral indicators.
Methods
Patients
A total of 40 consecutive patients admitted to our outpatient clinic (Hepatology Unit, University of Rome 'Tor Vergata', Rome, Italy) for the treatment of HCV genotype 1 chronic hepatitis were enrolled in the study. Baseline characteristics are reported in Table  1 . All patients gave their written informed consent to participate in the study, which was approved by the Ethical Committee of our institution (University of Rome 'Tor Vergata') and was in compliance with the 1975 Declaration of Helsinki. Patients were scheduled for a standard 48 weeks of antiviral therapy according to current guidelines with pegylated interferon (PEG-IFN)-α2a (180 µg/weekly via subcutaneous injection; Pegasys ® ; Roche S.p.A., Milan, Italy) and ribavirin (200 mg tablets; 5 or 6 tablets daily according to body weight ≤75 or >75 kg, respectively; Rebetol ® ; Schering-Plough S.p.A., Milan, Italy). Inclusion criteria were age >18 and <70 years of age, no previous treatment or absolute contraindications to PEG-IFN and ribavirin administration, no clinical or histological signs of established cirrhosis and no concomitant serious illness. Blood samples, for assessment of plasma and erythrocyte ribavirin concentration, were harvested at week 12 and week 24 during treatment. These time points were chosen because in patients undergoing concomitant treatment with PEG-IFN, the steady-state γ phase half-life of ribavirin is reported to be between 7 and 11 weeks [20] . Peripheral blood was collected in the morning before ribavirin consumption (trough value) in ethylene diamine tetra acetic acid tubes. Epoetin was not administered in these patients because its use during antiviral treatment of chronic hepatitis C was only permitted by the Italian Ministry of Public Health after February 2008, when the study enrolment was already completed.
Reagents
All chemicals, HPLC or reagent grade, were purchased from Sigma-Aldrich (Milan, Italy) unless otherwise specified.
Sample preparation for plasma and erythrocyte ribavirin assessment
Ribavirin assessment in plasma and erythrocytes was carried out as described and validated previously [21, 22] . For plasma ribavirin dosage, peripheral whole blood was centrifuged (1,500 g at 4°C 3-methylcitidine in double distilled water) and 500 µl of ammonium phosphate buffer (250 mM, pH 8.5) were added. Samples were then loaded on phenyl boronic acid (PBA) cartridges (100 mg; Bond Elute PBA; Varian, Inc., Turin, Italy) previously washed with 1 ml of 100 mM formic acid and 5 ml of 250 mM ammonium phosphate buffer (pH 8.5). Samples were then washed with 5 ml of 250 mM ammonium phosphate buffer (pH 8.5) and ribavirin was column extracted with 1 ml of 100 mM formic acid. For erythrocyte ribavirin assessment, whole blood samples (20 µl) were diluted with double distilled water (120 µl) and vortexed for 30 s to achieve complete haemolysis. Samples then underwent acid phosphatase treatment in order to obtain dephosphorylated metabolites. The reaction mixture was composed of 200 µl Tris-HCl (30 µM), 20 µl sodium acetate (1 M), acid phosphatase (2 U) and emolysate (140 µl).
Samples were then incubated for 1 h at 37°C and the reaction was stopped with 2.5 µl KOH (10 N). Samples were then loaded on PBA cartridges and purified as described above for plasma samples.
HPLC quantification of ribavirin
We used a Gilson HPLC system (Villers La Belle, France) equipped with a 5 µm ODS2 Spherisorb column (Phase Separation, Norwalk, CT, USA) and a diode array detector (Applied Biosystems, Foster City, CA, USA) set at 225 nm. The mobile phase was composed of 10 mM ammonium phosphate buffer (pH 2.5) at a flow rate of 0.7 ml/min. Plasma and whole blood samples, prepared as described above, were evaporated under nitrogen and reconstituted with mobile phase (200 µl). A 30 µl aliquot of each samples was injected in the column. Erythrocyte ribavirin concentration was then extrapolated as described previously [21, 22] , according to the formula Cer=(Cb-Cp )/Hct where Cer is the concentration of ribavirin in the erythrocytes, Cb is the concentration of ribavirin in whole blood, Cp is the plasmatic concentration of ribavirin and Hct corresponds to the hematocrit.
Biochemical and virological assessment
Common biochemical parameters assessed in the central laboratory facilities of our hospital (Policlinico di Tor Vergata, University of Rome 'Tor Vergata') were monitored and recorded during treatment. Quantitative HCV RNA determination was carried out with a sensitive PCR-based assay (lower limit of detection <60 IU/ml; Amplicor; Roche Diagnostics, Milan, Italy). EVR was defined as negativity or a decrease of >2 log of HCV RNA at week 24 of therapy. SVR was verified by HCV RNA negativity at 6 months after therapy withdrawal. HCV genotypes were assessed using a line-probe assay (Inno-Lipa HCV; Innogenetics, Gent, Belgium).
Statistical analyses
Data were analysed using the NCSS software package 2001 (Kaysville, UT, USA). Quantitative variable statistics were obtained using the Student's t-test and qualitative variables were analysed using Fisher's exact test. A P-value of ≤0.05 was regarded as statistically significant. Receiver operating characteristic (ROC) curves were designed to identify cutoff values for specific continuous variables, such as ribavirin blood levels.
Results
Patient characteristics and virological outcome during and at the end of treatment 
Plasma and erythrocyte ribavirin levels according to virological outcome
The plasma and erythrocyte ribavirin levels at weeks 12 and 24 of treatment, according to different virological outcomes, are reported in Table 2 . In order to evaluate whether different distribution of ribavirin between plasma and erythrocytes might be related to virological outcome, the plasma ribavirin/erythrocyte ribavirin ×100 ratio was also calculated. There were no differences at week 12 among patients who obtained or did not obtain EVR or SVR. No differences were observed at week 12 in the subgroup analysis of EVR patients according to SVR. By contrast, at week 24, EVR patients who achieved SVR showed statistically higher ribavirin levels in plasma and lower levels in erythrocytes as compared with those not achieving SVR (P=0.02 and P=0.03, respectively). These observations were corroborated by a concomitant statistical difference between the two groups with respect to the plasma ribavirin/erythrocyte ribavirin ×100 ratio (P<0.01). In order to assess the possible effects of haemoglobin levels and cumulative ribavirin dose on virological outcome or ribavirin blood levels, the groups were also compared on the basis of these variables. As shown in Table 3 , there was no difference between groups with regards to haemoglobin serum levels at baseline as well as at 12 and 24 weeks of treatment (when ribavirin assessment in the blood was carried out). Ribavirin cumulative doses also showed no significant differences.
Sensitivity, specificity, NPV and PPV of ribavirin assessment in blood
In order to identify cutoff values to assess specificity and sensitivity of plasma ribavirin, erythrocyte ribavirin and plasma ribavirin/erythrocyte ribavirin ×100 ratio at week 24, individual ROC curves were designed. The cutoff values for plasma, erythrocyte and plasma ribavirin/erythrocyte ribavirin ×100 ratio were 5 µM, 818 µM and 0.71 µM, respectively (area under the curve 0.7, 0.6 and 0.9, respectively). The calculated sensitivity and specificity for each parameter are reported, together with dot plot analysis, in Figure 1 . The corresponding negative predictive value (NPV) and positive predictive value (PPV) are reported in Table 4 together with those of EVR. As previously reported by another study, EVR was confirmed to have a strong NPV in identifying all non-responders (P<0.05 in comparison with erythrocyte ribavirin and plasma ribavirin/erythrocyte ribavirin ×100 ratio) at 3 months. By contrast, the highest PPV was shown by week 24 plasma ribavirin/erythrocyte ribavirin ×100 ratio, which was able to indentify EVR patients who achieved SVR with a 90% accuracy (P<0.05 in comparison with EVR and erythrocyte ribavirin).
Discussion
The end point of antiviral treatment in chronic hepatitis C is SVR, yet the rate at which this goal can be achieved is unsatisfactory and is currently restricted to approximately 50% of all treated patients [23] . For this reason, there is a growing awareness of the importance of preand on-treatment predictors that might be useful in conducting a successful therapeutic course. Routinely used on-treatment predictors are mainly based on viral load decay in serum [7, 10, 24, 25] . RVR has been recognized as an important indicator of SVR. Unfortunately, RVR is achieved in only approximately 20% of treated HCV genotype-1-infected patients, excluding a significant proportion of patients with a favourable therapeutic outcome. RVR is currently regarded as an element supporting the choice of an individualized short-term treatment [11] , but not as a stopping rule. By contrast, EVR has shown an optimal NPV because no more than 2% of patients who fail to reach this result will eventually reach SVR; however, the PPV of EVR is only 60% in HCV genotype-1-infected patients, meaning that 4 out of 10 patients are treated with no chance of obtaining SVR even if their on-treatment predictors are compatible. In this perspective, high PPV on-treatment predictors would be helpful, particularly in HCV genotype-1-infected patients obtaining EVR.
Since its introduction in the early 1990s, ribavirin has become a cornerstone in the treatment of chronic hepatitis C. Although early studies reported unsatisfactory results when ribavirin was used as monotherapy [26, 27] , the combined treatment with either standard IFN or PEG-IFN always showed superior results as compared with interferon alone [28, 29] . At present, the association of PEG-IFN and ribavirin is regarded as the standard approved treatment for chronic hepatitis C [23] . In this setting, adherence to therapy, intended as an adequate dosage of drugs for an adequate time span, has been considered of paramount importance [13] . An inadequate dose of ribavirin has been reported as an important on-treatment factor in the failure to achieve SVR [5] . This finding has been corroborated by several studies, indicating that ribavirin exposure is of crucial importance in achieving virological response both in HCV or HCV-HIV-coinfected patients [30, 31] . A recent pharmacokinetic-pharmacodynamic study conducted on a limited number of patients reported that a crucial area under the curve of plasma ribavirin after the first dose was highly predictive of SVR [17] . This finding was partially in disagreement with a previous study on HCV-HIV-coinfected patients that reported that during the first 4 weeks of treatment, median plasma ribavirin levels and the area under the ribavirin curve were significantly lower in responders compared with nonresponders [32] . Other authors, with an approach similar to that used in the present study, investigated serum or plasma ribavirin levels as a function of viral response in HCV or HCV-HIV-coinfected patients [33] [34] [35] [36] [37] [38] . The results of these studies were not conclusive because of several weaknesses and heterogeneity. For example, data on plasma or serum were similarly reported despite the latter being scarcely reproducible, there was no uniformity in patients genotypes, some studies were conducted on patients with HIV coinfection and others included patients who were non-responders to a previous treatment. Despite these diversities, there was some agreement on the findings that increased ribavirin serum or plasma levels were associated with an increased probability of obtaining SVR. Notably, one of these studies that defined a cutoff value at week 4 for plasma ribavirin concentration reported a sensitivity of 73% and a specificity of 80% in predicting SVR [38] . The results of this research should be critically revised considering that the majority of selected patients were non-responders to a previous similar treatment so that these results might not be completely extrapolated to the general untreated HCV population. In addition, the concentration of ribavirin in plasma at week 4 might still be in a fluctuation phase because the steady-state half-life of ribavirin is reported to be achieved between 7 and 11 weeks of treatment.
In the present study, we reassessed this issue in the later phases of treatment and we also considered the possible importance of simultaneous assessment of erythrocyte ribavirin concentration, as already suggested by others [17, 32] . Erythrocyte ribavirin concentration might not be considered representative of drug distribution in parenchymal cells because red blood cells lack the enzymes to catabolise the ribavirin nucleotide and, as a consequence, undergo a progressive accumulation of the drug [17, 39] . By contrast, their role as a reservoir for ribavirin in a possible relationship with therapeutic effect as well as with adverse events has been postulated [40] . Our data confirm the direct relationship between adequate plasma levels of ribavirin and achievement of SVR; they also demonstrate that there is a significant difference in erythrocyte ribavirin concentration at week 24 between EVR patients who will obtain SVR and those who will not obtain SVR, and a major role in achieving SVR is determined by the optimal partition of the drug between plasma and erythrocytes. Accordingly, the plasma ribavirin/erythrocyte ribavirin ×100 ratio was able to identify patients who achieved SVR with an accuracy of 90%. We are aware that the extrapolation of our results to different patient cohorts (for geographical, therapeutic or clinical reasons) is not guaranteed; however, our data indicate a promising strategy to monitor treatment response during antiviral therapy for genotype 1 chronic hepatitis C. In addition, ribavirin assessment (both in plasma and red blood cells) could be useful as a guide in designing new clinical trials aimed to individualize dosage in HCV therapy. At present, factors contributing to a different distribution of ribavirin in plasma or erythrocytes are unclear. Alterations of cationic membrane transporters during ribavirin therapy and consequent membrane oxidative damage have been reported in the early phase of treatment (<4 weeks) [41] . Possible longterm adjustments in the course of therapy, as suggested by our study, have so far not been investigated. Our data suggest that an increased capacity for accumulating ribavirin in red blood cells during the late phase of therapy might be responsible for a lower distribution of the drug in plasma and thus reducing its availability in the liver. In this context, haematological individual factors (such as different levels of adenosine triphosphate, which act as an antioxidant against ribavirin effects [41] ) or a variable state of density of red blood cells (as determined by specific Ca
2+
-sensitive K + [Gardos] channel [42] ), might play an important, although still unexamined, role.
In conclusion, our study demonstrates that plasma ribavirin/erythrocyte ribavirin ×100 ratio at week 24 might predict SVR in previously untreated HCV genotype-1-infected patients undergoing standard therapy for chronic hepatitis C. This parameter has a better PPV compared with the on-treatment predictors currently used; however, clinical strategies, such as ribavirin dose adjustment or use of other drugs, which might optimize distribution of ribavirin among plasma and red blood cells in order to obtain SVR, remain to be assessed. ribavirin ×100 ratio at 24 weeks
The cutoff values for plasma ribavirin, erythrocyte ribavirin and plasma ribavirin/erythrocyte ribavirin ×100 ratio were 5 µM, 818 µM and 0.71 µM, respectively. a Difference was statistically significant in comparison with erythrocyte ribavirin and plasma ribavirin/erythrocyte ribavirin ×100 ratio. b Difference was statistically significant in comparison with early virological response (EVR) and erythrocyte ribavirin. NPV, negative predictive value; PPV, positive predictive value. Table 4 . Calculated NPV and PPV of plasma ribavirin, erythrocyte ribavirin and plasma ribavirin/erythrocyte ribavirin ×100 ratio in patients obtaining EVR
